OncoMatch

OncoMatch/Clinical Trials/NCT05266898

Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV

Is NCT05266898 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies multiple treatments including Human papillomavirus 9-valent vaccine, recombinant and human papillomavirus vaccine, recombinant for papillomavirus vaccines.

Phase 4RecruitingLouisiana State University Health Sciences Center in New OrleansNCT05266898Data as of May 2026

Treatment: Human papillomavirus 9-valent vaccine, recombinant · human papillomavirus vaccine, recombinantThe primary objective of this study is to determine the magnitude and breadth of the serum antibody response to the nonavalent HPV vaccine (Gardasil-9) in adults with well-controlled HIV infection. The secondary objectives of the study are to observe short term clinical outcomes of prevalent HPV genotype-specific anogenital infections in adults living with HIV who complete the three-dose Gardasil-9 vaccine series, and to determine the protection afforded by Gardasil vaccine over time in previously vaccinated adults living with HIV. The clinical hypothesis is that adults with virologically controlled HIV mount a serum antibody response to the nonavalent HPV vaccine that is comparable to HIV negative counterparts. We also postulate that HPV vaccination will provide short-term clinical benefit against HPV infections and disease associated with vaccine genotypes and continuing protection against vaccine genotypes of HPV over time.

Check if I qualify

Extracted eligibility criteria

Biomarker criteria

Required: CD4 count >200 cells/ml (>200 cells/ml)

immune intact (CD4+ T cell count in peripheral blood >200 cells/ml)

Required: HIV viral load <1,000 genome copies/mL (<1,000 genome copies/mL)

HIV controlled (peripheral blood HIV viral load <1,000 genome copies/mL)

Prior therapy

Must have received: antiretroviral therapy

Stable on antiretroviral regimen for ≥3 months

Cannot have received: blood transfusion or blood products

Received blood transfusion/blood products within the past 6 months

Cannot have received: other vaccine products

Recipients of other vaccine products within the past month

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • University Medical Center New Orleans · New Orleans, Louisiana

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify